SVB Leerink Maintains Market Perform Rating for Aligos Therapeutics: Here's What You Need To Know

SVB Leerink has decided to maintain its Market Perform rating of Aligos Therapeutics (NASDAQ:ALGS) and lower its price target from $3.00 to $2.00.

Shares of Aligos Therapeutics are trading up 0.0% over the last 24 hours, at $1.07 per share.

A move to $2.00 would account for a 86.92% increase from the current share price.

About Aligos Therapeutics

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company’s pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish “analyst ratings” for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Leave a Reply

Your email address will not be published. Required fields are marked *